The VAC regimen for adult rhabdomyosarcoma: Differences between adolescent/young adult and older patients.

There were no significant differences in responses to the VAC among AYA and older patients with RMS. With the appropriate dose modification, the VAC regimen could be a feasible treatment option for RMS patients >40 years old.